Galectin-3 Inhibitors via Modular Carbohydrate Warheads
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and disorders related to galectin-3 binding to natural ligands are inadequate, as galectin-3 is involved in various pathological processes including inflammatory/autoimmune diseases, fibrosis, and cancer, and existing galectin-3 inhibitors have limitations in efficacy and specificity.
Innovation Solution
Development of novel compounds of formula (I) that act as galectin-3 inhibitors, which can modulate galectin-3 binding to its natural carbohydrate ligands, thereby preventing or treating diseases related to galectin-3 activity. These compounds are designed to be used alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing galectin-3 inhibitors are used, then some therapeutic effect is achieved, but efficacy and specificity are limited
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features at different positions: the N-terminal region targets the carbohydrate recognition domain for specific ligand binding, while the C-terminal region is optimized for high-affinity interaction with galectin-3. This regional optimization of molecular properties enhances both specificity and efficacy independently.
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecules that combine carbohydrate-like warhead structures with peptide-like backbones. This composite design allows the inhibitor to simultaneously engage multiple binding interfaces on galectin-3, achieving both high specificity for the target protein and high therapeutic efficacy through multi-point binding.
2Reliability
If galectin-3 inhibition is enhanced, then therapeutic benefits increase, but potential off-target effects may worsen
Solution Approach 1:
The patent uses carbohydrate-mimicking warhead structures as intermediaries that specifically recognize and bind to the carbohydrate recognition domain of galectin-3. These intermediary structures act as decoys that selectively engage the target protein's natural binding site, preventing galectin-3 from interacting with its natural carbohydrate ligands while avoiding off-target effects through high selectivity.
Solution Approach 2:
The patent applies parameter changes by systematically varying the chemical properties of the inhibitor molecules, including the warhead structure, linker length and composition, and C-terminal amino acid sequence. By optimizing these parameters, the patent achieves enhanced binding affinity and specificity for galectin-3, thereby increasing therapeutic benefit while minimizing off-target effects through precise parameter control.
3Reliability
If compound structure is optimized for binding affinity, then inhibition efficacy improves, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into three distinct modular components: an N-terminal carbohydrate-like warhead, a peptide-like linker region, and a C-terminal amino acid sequence. Each module can be independently optimized for binding affinity and then assembled through standardized coupling reactions, thereby achieving high binding affinity without proportionally increasing synthesis complexity.
Solution Approach 2:
The patent employs universality by designing a platform approach where the central peptide-like backbone and coupling chemistry can be used across multiple inhibitor variants. This universal framework allows different warhead and C-terminal combinations to be synthesized using the same core methodology, reducing overall synthesis complexity while enabling optimization of binding affinity through systematic variation of terminal regions.
Data Source
AI summary
The present invention relates to compounds of Formula (I)wherein Ar1, Ar2, L, n, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.